MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Lixte Biotechnology Holdings Total Assets 2011-2026 | LIXT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.31 M | 5.56 M | 5.09 M | 5.23 M | 2.67 M | 4.34 M | 1.37 M | 433 K | 598 K | 539 K | 560 K | 1.75 M | 430 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.56 M | 430 K | 2.53 M |
Quarterly Total Assets Lixte Biotechnology Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.43 M | 1.19 M | 1.15 M | 1.7 M | 2.67 M | 4.31 M | 5.23 M | 3.1 M | 4.33 M | 5.56 M | 6.82 M | 8.02 M | 4.12 M | 5.09 M | 6.33 M | 7.24 M | 7.89 M | 5.23 M | 5.23 M | 5.23 M | 5.23 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 433 K | 433 K | 433 K | 433 K | 598 K | 598 K | 598 K | 598 K | 539 K | 539 K | 539 K | 539 K | 558 K | 558 K | 558 K | 558 K | 1.75 M | 1.75 M | 1.75 M | 1.75 M | 430 K | 430 K | 430 K | 430 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.02 M | 430 K | 2.66 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
134 B | $ 212.08 | 0.45 % | $ 375 B | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.29 | -1.94 % | $ 983 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
337 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
513 M | $ 12.29 | -11.96 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
27.7 M | $ 1.08 | -1.38 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
8.23 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
751 M | $ 16.55 | -4.11 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 319.85 | -2.53 % | $ 41.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
94.6 M | $ 4.34 | -2.47 % | $ 832 M | Canada |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
86.6 M | - | - | $ 384 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
286 M | - | - | $ 1.41 B | Canada |